Company news
Summit Therapeutics Inc. (NASDAQ:SMMT) news
Summit Therapeutics Inc. news releases on 6ix. Latest, Feb 24, 2025: Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth…
Press releases — page 2
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Twelve Months Ended December 31, 2024
February 23, 2025
Summit Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Ivonescimab in Combination with Pfizer Antibody Drug Conjugates (ADCs)
February 23, 2025
Summit Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results & Operational Progress Call on February 24, 2025
February 17, 2025
Summit Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 6, 2025
Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024
October 29, 2024
Summit Therapeutics to Host Third Quarter 2024 Financial Results & Operational Progress Call on October 30, 2024
October 22, 2024
Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC
October 2, 2024
Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024
September 15, 2024
Summit Therapeutics Raises $235 Million
September 11, 2024
Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in China
September 7, 2024
HARMONi-2, Featuring Ivonescimab Monotherapy vs. Pembrolizumab Monotherapy, to be Showcased in Presidential Symposium at WCLC 2024
August 11, 2024
Two Ivonescimab (PD-1/VEGF) Results including Phase 3 Monotherapy versus Pembrolizumab Monotherapy in First-Line Treatment for PD-L1 Positive NSCLC to Be Presented at WCLC 2024
August 10, 2024
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2024
August 5, 2024
Summit Therapeutics to Host Second Quarter 2024 Financial Results & Operational Progress Call on August 6, 2024
July 28, 2024
Summit Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Development of Ivonescimab
July 24, 2024
Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors
June 26, 2024
Summit Raises $200 Million; Also Expands License Territories for Ivonescimab
June 2, 2024
Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA
May 31, 2024
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
May 30, 2024
Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China
May 29, 2024
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024
April 30, 2024
Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024
April 23, 2024
Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors
April 10, 2024
Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum
April 9, 2024
Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024
March 13, 2024
Summit Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
March 4, 2024
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023
February 19, 2024
Summit Therapeutics to Host Fourth Quarter & Full Year 2023 Financial Results & Operational Progress Call on February 20, 2024
February 13, 2024
Summit Therapeutics to Present at Oppenheimer’s 34th Annual Healthcare Life Sciences Conference
February 6, 2024
Summit Therapeutics Announces Updated Phase II Data for Ivonescimab at 42nd Annual J.P. Morgan Healthcare Conference
January 7, 2024
Summit Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 2, 2024
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023
November 6, 2023
Laura Chow, MD, Cancer Immunotherapy Trailblazer, Joins Summit as Senior Vice President of Clinical Development
November 1, 2023
Ivonescimab's Novel Mechanism of Action Highlighting Cooperative Binding to be Featured in Poster Presentation at SITC 2023
November 1, 2023
Ivonescimab’s Novel Mechanism of Action Highlighting Cooperative Binding to be Featured in Poster Presentation at SITC 2023
October 30, 2023
Summit Therapeutics to Host Q3 2023 Financial Results & Operational Progress Call on November 7, 2023
October 25, 2023
H. Jack West, MD, Renowned Oncologist & Lung Cancer Expert, Joins Summit Therapeutics as Vice President of Clinical Development
October 18, 2023
Summit Therapeutics Appoints Proven Biotech Leader Manmeet S. Soni as Chief Operating Officer
October 15, 2023
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2023
August 8, 2023
Summit Therapeutics to Host Q2 2023 Financial Results & Operational Progress Call on August 9, 2023
August 1, 2023
Promising Data for Investigational Innovative Bispecific Ivonescimab Featured at ASCO 2023
June 3, 2023
Ivonescimab Updated Data to be Featured at ASCO 2023
May 31, 2023
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2023
May 10, 2023
Summit Therapeutics Announces First Patient Treated in Phase III HARMONi Clinical Trial Evaluating Ivonescimab (SMT112)
May 8, 2023
Summit Therapeutics Announces Initial Indications for Clinical Trials for Ivonescimab (SMT112)
May 2, 2023
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2022
March 8, 2023
Summit Therapeutics Closes Fully-Subscribed $500 Million Rights Offering
March 2, 2023
Summit Therapeutics’ Rights Offering Nearing Expiration Date
February 22, 2023
Summit Therapeutics Announces Timing for Rights Offering for Up to $500 Million
January 29, 2023
Summit Therapeutics Closes Deal with Akeso Inc. to In-License Breakthrough Innovative Bispecific Antibody
January 19, 2023